Bioxtran has live a online interview at the market open tomorrow,
and they cancelled a massive number of common shares:
https://www.otcmarkets.com/filing/html?id=177...a8BtcUsX0h
"On August 19, 2024, the Company issued 28,971,248 shares of Convertible Preferred Stock, with a par value of $0.001 per share, to company insiders **in exchange for 94,057,658 shares of Common Stock, at a 5:1 basis,** as per the Certificate of Designation dated April 19, 2024, $353,840 in accrued salaries, accounts receivable and other short-term debt, and of exercise of the conversion rights for the 14,410,000 (49%) Subsidiary shares as per option agreement dated November 20, 2021. The Preferred shares can at any time be converted back into shares of Common Stock at a 1:5 basis, and carry a voting-power of an “as if converted” basis multiplied by a factor of two."
https://www.otcmarkets.com/filing/html?id=177...a8BtcUsX0h
**A 50% Common reduction in sharecount!** (OS is about 30 Million now)
$BIXT bounced off the double bottom that started right away a day ago.
In 2 days, at the market Open, BIXT is live in a follow up interview, link below.
This means more eyes on the stock, that **scored a massive 10 Million dollar grant from the HEME Foundation to complete bringing to market a synthetic, non toxic, Nano-Carbohydrate HEME iron oxygen blood carrying molecule, that is shelf stable for use with Blood plasma in minutes, and that can by pass blood clots to get live saving oxygen to the heart, organs and brain.**
You can sign up** for free** to **watch live here at the market open **8/22/2024 (THursday morning):
https://goto.webcasts.com/starthere.jsp?ei=16...p;sti=icon
and they cancelled a massive number of common shares:
https://www.otcmarkets.com/filing/html?id=177...a8BtcUsX0h
"On August 19, 2024, the Company issued 28,971,248 shares of Convertible Preferred Stock, with a par value of $0.001 per share, to company insiders **in exchange for 94,057,658 shares of Common Stock, at a 5:1 basis,** as per the Certificate of Designation dated April 19, 2024, $353,840 in accrued salaries, accounts receivable and other short-term debt, and of exercise of the conversion rights for the 14,410,000 (49%) Subsidiary shares as per option agreement dated November 20, 2021. The Preferred shares can at any time be converted back into shares of Common Stock at a 1:5 basis, and carry a voting-power of an “as if converted” basis multiplied by a factor of two."
https://www.otcmarkets.com/filing/html?id=177...a8BtcUsX0h
**A 50% Common reduction in sharecount!** (OS is about 30 Million now)
$BIXT bounced off the double bottom that started right away a day ago.
In 2 days, at the market Open, BIXT is live in a follow up interview, link below.
This means more eyes on the stock, that **scored a massive 10 Million dollar grant from the HEME Foundation to complete bringing to market a synthetic, non toxic, Nano-Carbohydrate HEME iron oxygen blood carrying molecule, that is shelf stable for use with Blood plasma in minutes, and that can by pass blood clots to get live saving oxygen to the heart, organs and brain.**
You can sign up** for free** to **watch live here at the market open **8/22/2024 (THursday morning):
https://goto.webcasts.com/starthere.jsp?ei=16...p;sti=icon
